http://www.drugs.com/fda_alerts.html Latest alerts to consumers and health care providers warning of recently identified adverse effects associated with currently available drugs and supplements. en http://www.drugs.com/http://www.drugs.com/img/drugscom-feedburner.gif http://feeds.drugs.com/~r/Drugscom-FdaMedwatchAlerts/~3/ugXgT0RwT6k/saphris-asenapine-maleate-safety-communication-serious-allergic-reactions-13022.html Audience: Psychiatry, Patients [Posted 09/01/2011] ISSUE: FDA notified healthcare professionals and patients that serious allergic reactions have been reported with the use of Saphris (asenapine maleate). The Contraindications, Warnings and... <p><a href="http://feedads.g.doubleclick.net/~a/JcfLpeofcPEm0VJM4koWKDgUAeo/0/da"><img src="http://feedads.g.doubleclick.net/~a/JcfLpeofcPEm0VJM4koWKDgUAeo/0/di" border="0" ismap="true"></img></a><br/> <a href="http://feedads.g.doubleclick.net/~a/JcfLpeofcPEm0VJM4koWKDgUAeo/1/da"><img src="http://feedads.g.doubleclick.net/~a/JcfLpeofcPEm0VJM4koWKDgUAeo/1/di" border="0" ismap="true"></img></a></p><img src="http://feeds.feedburner.com/~r/Drugscom-FdaMedwatchAlerts/~4/ugXgT0RwT6k" height="1" width="1"/> Thu, 01 Sep 2011 04:00:00 GMT http://www.drugs.com/fda/saphris-asenapine-maleate-safety-communication-serious-allergic-reactions-13022.html http://feeds.drugs.com/~r/Drugscom-FdaMedwatchAlerts/~3/Beh6BcyAvLU/reclast-zoledronic-acid-safety-communication-new-updated-warning-kidney-impairment-13020.html Audience: Endocrinology, Pharmacy, Patient ISSUE: FDA notified healthcare professionals and patients of an update to the drug label for Reclast (zoledronic acid) regarding the risk of kidney failure. Cases of acute renal failure requiring dialysis... <p><a href="http://feedads.g.doubleclick.net/~a/WPZbnNPxQPvEqx1Y68wY49J9siI/0/da"><img src="http://feedads.g.doubleclick.net/~a/WPZbnNPxQPvEqx1Y68wY49J9siI/0/di" border="0" ismap="true"></img></a><br/> <a href="http://feedads.g.doubleclick.net/~a/WPZbnNPxQPvEqx1Y68wY49J9siI/1/da"><img src="http://feedads.g.doubleclick.net/~a/WPZbnNPxQPvEqx1Y68wY49J9siI/1/di" border="0" ismap="true"></img></a></p><img src="http://feeds.feedburner.com/~r/Drugscom-FdaMedwatchAlerts/~4/Beh6BcyAvLU" height="1" width="1"/> Thu, 01 Sep 2011 04:00:00 GMT http://www.drugs.com/fda/reclast-zoledronic-acid-safety-communication-new-updated-warning-kidney-impairment-13020.html http://feeds.drugs.com/~r/Drugscom-FdaMedwatchAlerts/~3/-gNQA8Cs-n8/h-38-p-industries-povidone-iodine-swabsticks-prep-solutions-scrub-solutions-prep-gel-recall-13018.html Audience: Pharmacy, Consumer, Risk Manager ISSUE: H & P Industries and FDA notified health professionals and the public of a recall of all lots (lots beginning with 8J-8M, 9A-9M, 0A-0M, 1A-1C) of Povidone Iodine Swabsticks, Prep Solutions, Scrub... <p><a href="http://feedads.g.doubleclick.net/~a/VjcX5FYsmfBdpGZFFbucZZw_wDk/0/da"><img src="http://feedads.g.doubleclick.net/~a/VjcX5FYsmfBdpGZFFbucZZw_wDk/0/di" border="0" ismap="true"></img></a><br/> <a href="http://feedads.g.doubleclick.net/~a/VjcX5FYsmfBdpGZFFbucZZw_wDk/1/da"><img src="http://feedads.g.doubleclick.net/~a/VjcX5FYsmfBdpGZFFbucZZw_wDk/1/di" border="0" ismap="true"></img></a></p><img src="http://feeds.feedburner.com/~r/Drugscom-FdaMedwatchAlerts/~4/-gNQA8Cs-n8" height="1" width="1"/> Fri, 26 Aug 2011 04:00:00 GMT http://www.drugs.com/fda/h-38-p-industries-povidone-iodine-swabsticks-prep-solutions-scrub-solutions-prep-gel-recall-13018.html http://feeds.drugs.com/~r/Drugscom-FdaMedwatchAlerts/~3/16L__GdVRn0/celexa-citalopram-hydrobromide-safety-communication-abnormal-heart-rhythms-associated-doses-13017.html Audience: Psychiatry, Cardiology ISSUE: FDA notified healthcare professionals and patients that the antidepressant Celexa (citalopram hydrobromide) should no longer be used at doses greater than 40 mg per day because it can cause abnormal changes in... <p><a href="http://feedads.g.doubleclick.net/~a/-fFw_I0V3_mHKQ788dMgPpIgV0Q/0/da"><img src="http://feedads.g.doubleclick.net/~a/-fFw_I0V3_mHKQ788dMgPpIgV0Q/0/di" border="0" ismap="true"></img></a><br/> <a href="http://feedads.g.doubleclick.net/~a/-fFw_I0V3_mHKQ788dMgPpIgV0Q/1/da"><img src="http://feedads.g.doubleclick.net/~a/-fFw_I0V3_mHKQ788dMgPpIgV0Q/1/di" border="0" ismap="true"></img></a></p><img src="http://feeds.feedburner.com/~r/Drugscom-FdaMedwatchAlerts/~4/16L__GdVRn0" height="1" width="1"/> Wed, 24 Aug 2011 04:00:00 GMT http://www.drugs.com/fda/celexa-citalopram-hydrobromide-safety-communication-abnormal-heart-rhythms-associated-doses-13017.html http://feeds.drugs.com/~r/Drugscom-FdaMedwatchAlerts/~3/0zaCeMGwMl8/vasopressin-usp-multiple-vials-recall-sub-potency-13016.html Audience: Risk Manager, Pharmacy ISSUE: American Regent, Inc. is conducting a nationwide voluntary recall of multiple lots of Vasopressin Injection, USP to the Retail/Hospital level. This product recall was initiated by American Regent, Inc. because... <p><a href="http://feedads.g.doubleclick.net/~a/repdWpsTtEqdOilUB--XG5_qADc/0/da"><img src="http://feedads.g.doubleclick.net/~a/repdWpsTtEqdOilUB--XG5_qADc/0/di" border="0" ismap="true"></img></a><br/> <a href="http://feedads.g.doubleclick.net/~a/repdWpsTtEqdOilUB--XG5_qADc/1/da"><img src="http://feedads.g.doubleclick.net/~a/repdWpsTtEqdOilUB--XG5_qADc/1/di" border="0" ismap="true"></img></a></p><img src="http://feeds.feedburner.com/~r/Drugscom-FdaMedwatchAlerts/~4/0zaCeMGwMl8" height="1" width="1"/> Thu, 04 Aug 2011 04:00:00 GMT http://www.drugs.com/fda/vasopressin-usp-multiple-vials-recall-sub-potency-13016.html http://feeds.drugs.com/~r/Drugscom-FdaMedwatchAlerts/~3/M1xPKBSdVhs/recombinant-human-growth-hormone-somatropin-ongoing-safety-review-possible-increased-risk-death-13015.html Audience: Pediatrics, Endocrinology [UPDATED 08/04/2011] FDA has determined that, at this time, the evidence regarding recombinant human growth hormone and increased risk of death is inconclusive. In its analysis of the SAGhE study, FDA identified... <p><a href="http://feedads.g.doubleclick.net/~a/0qCjg2Tz81Ssvyny85kF0IIELfk/0/da"><img src="http://feedads.g.doubleclick.net/~a/0qCjg2Tz81Ssvyny85kF0IIELfk/0/di" border="0" ismap="true"></img></a><br/> <a href="http://feedads.g.doubleclick.net/~a/0qCjg2Tz81Ssvyny85kF0IIELfk/1/da"><img src="http://feedads.g.doubleclick.net/~a/0qCjg2Tz81Ssvyny85kF0IIELfk/1/di" border="0" ismap="true"></img></a></p><img src="http://feeds.feedburner.com/~r/Drugscom-FdaMedwatchAlerts/~4/M1xPKBSdVhs" height="1" width="1"/> Thu, 04 Aug 2011 04:00:00 GMT http://www.drugs.com/fda/recombinant-human-growth-hormone-somatropin-ongoing-safety-review-possible-increased-risk-death-13015.html http://feeds.drugs.com/~r/Drugscom-FdaMedwatchAlerts/~3/AIwoartvVno/diflucan-fluconazole-safety-communication-long-term-during-pregnancy-may-associated-birth-defects-13013.html Audience: OBGYN, Pharmacy, Infectious Disease ISSUE: FDA is informing the public that treatment with chronic, high doses (400-800mg/day) of Diflucan (fluconazole) during the first trimester of pregnancy may be associated with a rare and distinct set... <p><a href="http://feedads.g.doubleclick.net/~a/Lr_sYISostqelV6LZMOfVKOhCFQ/0/da"><img src="http://feedads.g.doubleclick.net/~a/Lr_sYISostqelV6LZMOfVKOhCFQ/0/di" border="0" ismap="true"></img></a><br/> <a href="http://feedads.g.doubleclick.net/~a/Lr_sYISostqelV6LZMOfVKOhCFQ/1/da"><img src="http://feedads.g.doubleclick.net/~a/Lr_sYISostqelV6LZMOfVKOhCFQ/1/di" border="0" ismap="true"></img></a></p><img src="http://feeds.feedburner.com/~r/Drugscom-FdaMedwatchAlerts/~4/AIwoartvVno" height="1" width="1"/> Wed, 03 Aug 2011 04:00:00 GMT http://www.drugs.com/fda/diflucan-fluconazole-safety-communication-long-term-during-pregnancy-may-associated-birth-defects-13013.html http://feeds.drugs.com/~r/Drugscom-FdaMedwatchAlerts/~3/2Ria0b2d7Iw/slim-forte-slimming-capsules-slim-forte-slimming-coffee-botanical-slimming-soft-gel-public-13009.html Audience: Consumer [Update 07/27/2011] - Intercharm Inc., is recalling Slimforte Slimming Capsules, Slimforte Slimming Coffee, and Botanical Slimming Soft Gel to the consumer/user level. These products are sold as dietary supplements and marketed... <p><a href="http://feedads.g.doubleclick.net/~a/vxScRWZLLBgs2FGr8vOvEDbVSzo/0/da"><img src="http://feedads.g.doubleclick.net/~a/vxScRWZLLBgs2FGr8vOvEDbVSzo/0/di" border="0" ismap="true"></img></a><br/> <a href="http://feedads.g.doubleclick.net/~a/vxScRWZLLBgs2FGr8vOvEDbVSzo/1/da"><img src="http://feedads.g.doubleclick.net/~a/vxScRWZLLBgs2FGr8vOvEDbVSzo/1/di" border="0" ismap="true"></img></a></p><img src="http://feeds.feedburner.com/~r/Drugscom-FdaMedwatchAlerts/~4/2Ria0b2d7Iw" height="1" width="1"/> Wed, 27 Jul 2011 04:00:00 GMT http://www.drugs.com/fda/slim-forte-slimming-capsules-slim-forte-slimming-coffee-botanical-slimming-soft-gel-public-13009.html http://feeds.drugs.com/~r/Drugscom-FdaMedwatchAlerts/~3/rWDTX-e-3o4/cardiogen-82-pet-scan-safety-communication-increased-radiation-exposure-13008.html Audience: Nuclear Medicine, Radiology, Patients [UPDATED 07/26/2011] FDA notified healthcare professionals to stop using CardioGen-82 for cardiac positron emission tomography (PET) scans. The manufacturer, Bracco Diagnostics, Inc. has decided to... <p><a href="http://feedads.g.doubleclick.net/~a/Q5FE5MIZLvSKV6P_XbNlVOwrtyA/0/da"><img src="http://feedads.g.doubleclick.net/~a/Q5FE5MIZLvSKV6P_XbNlVOwrtyA/0/di" border="0" ismap="true"></img></a><br/> <a href="http://feedads.g.doubleclick.net/~a/Q5FE5MIZLvSKV6P_XbNlVOwrtyA/1/da"><img src="http://feedads.g.doubleclick.net/~a/Q5FE5MIZLvSKV6P_XbNlVOwrtyA/1/di" border="0" ismap="true"></img></a></p><img src="http://feeds.feedburner.com/~r/Drugscom-FdaMedwatchAlerts/~4/rWDTX-e-3o4" height="1" width="1"/> Tue, 26 Jul 2011 04:00:00 GMT http://www.drugs.com/fda/cardiogen-82-pet-scan-safety-communication-increased-radiation-exposure-13008.html http://feeds.drugs.com/~r/Drugscom-FdaMedwatchAlerts/~3/ui8O-K_KTjg/zyvox-linezolid-safety-communication-serious-cns-reactions-possible-given-patients-certain-13007.html Audience: Infectious Disease, Psychiatry, Family Practice ISSUE: FDA has received reports of serious central nervous system (CNS) reactions when the antibacterial drug linezolid (Zyvox) is given to patients taking psychiatric medications that work... <p><a href="http://feedads.g.doubleclick.net/~a/1Ty-5Nl5-BKpatP4ltuNuTWN-R4/0/da"><img src="http://feedads.g.doubleclick.net/~a/1Ty-5Nl5-BKpatP4ltuNuTWN-R4/0/di" border="0" ismap="true"></img></a><br/> <a href="http://feedads.g.doubleclick.net/~a/1Ty-5Nl5-BKpatP4ltuNuTWN-R4/1/da"><img src="http://feedads.g.doubleclick.net/~a/1Ty-5Nl5-BKpatP4ltuNuTWN-R4/1/di" border="0" ismap="true"></img></a></p><img src="http://feeds.feedburner.com/~r/Drugscom-FdaMedwatchAlerts/~4/ui8O-K_KTjg" height="1" width="1"/> Tue, 26 Jul 2011 04:00:00 GMT http://www.drugs.com/fda/zyvox-linezolid-safety-communication-serious-cns-reactions-possible-given-patients-certain-13007.html http://feeds.drugs.com/~r/Drugscom-FdaMedwatchAlerts/~3/GV3x2mO0zQs/methylene-blue-safety-communication-serious-cns-reactions-possible-given-patients-certain-13006.html Audience: Emergency Medicine, Critical Care Medicine, Psychiatry ISSUE: FDA has received reports of serious central nervous system (CNS) reactions when the drug methylene blue is given to patients taking psychiatric medications that work through the... <p><a href="http://feedads.g.doubleclick.net/~a/juW_1xieCL3PdK-sPBX-yQES7UM/0/da"><img src="http://feedads.g.doubleclick.net/~a/juW_1xieCL3PdK-sPBX-yQES7UM/0/di" border="0" ismap="true"></img></a><br/> <a href="http://feedads.g.doubleclick.net/~a/juW_1xieCL3PdK-sPBX-yQES7UM/1/da"><img src="http://feedads.g.doubleclick.net/~a/juW_1xieCL3PdK-sPBX-yQES7UM/1/di" border="0" ismap="true"></img></a></p><img src="http://feeds.feedburner.com/~r/Drugscom-FdaMedwatchAlerts/~4/GV3x2mO0zQs" height="1" width="1"/> Tue, 26 Jul 2011 04:00:00 GMT http://www.drugs.com/fda/methylene-blue-safety-communication-serious-cns-reactions-possible-given-patients-certain-13006.html http://feeds.drugs.com/~r/Drugscom-FdaMedwatchAlerts/~3/vOPuP-2oVw8/chantix-varenicline-label-change-risk-certain-cardiovascular-adverse-events-13005.html Audience: Family Medicine, Cardiology [UPDATED 07/22/2011] FDA has approved an updated drug label for Chantix (varenicline) to include information about the efficacy and safety of the drug in two patient populations who may benefit greatly from... <p><a href="http://feedads.g.doubleclick.net/~a/nkEp8dLGO96RQ7l0cGXxAg-5Wqk/0/da"><img src="http://feedads.g.doubleclick.net/~a/nkEp8dLGO96RQ7l0cGXxAg-5Wqk/0/di" border="0" ismap="true"></img></a><br/> <a href="http://feedads.g.doubleclick.net/~a/nkEp8dLGO96RQ7l0cGXxAg-5Wqk/1/da"><img src="http://feedads.g.doubleclick.net/~a/nkEp8dLGO96RQ7l0cGXxAg-5Wqk/1/di" border="0" ismap="true"></img></a></p><img src="http://feeds.feedburner.com/~r/Drugscom-FdaMedwatchAlerts/~4/vOPuP-2oVw8" height="1" width="1"/> Fri, 22 Jul 2011 04:00:00 GMT http://www.drugs.com/fda/chantix-varenicline-label-change-risk-certain-cardiovascular-adverse-events-13005.html http://feeds.drugs.com/~r/Drugscom-FdaMedwatchAlerts/~3/cLlXitOErIY/multaq-dronedarone-safety-communication-increased-risk-death-serious-cardiovascular-events-13004.html Audience: Healthcare Professionals ISSUE: FDA notified healthcare professionals that it is reviewing data from a clinical trial that evaluated the effects of the antiarrhythmic drug Multaq (dronedarone) in patients with permanent atrial... <p><a href="http://feedads.g.doubleclick.net/~a/hsZPfyoVyJyrI0IvoeWHVg0vqOs/0/da"><img src="http://feedads.g.doubleclick.net/~a/hsZPfyoVyJyrI0IvoeWHVg0vqOs/0/di" border="0" ismap="true"></img></a><br/> <a href="http://feedads.g.doubleclick.net/~a/hsZPfyoVyJyrI0IvoeWHVg0vqOs/1/da"><img src="http://feedads.g.doubleclick.net/~a/hsZPfyoVyJyrI0IvoeWHVg0vqOs/1/di" border="0" ismap="true"></img></a></p><img src="http://feeds.feedburner.com/~r/Drugscom-FdaMedwatchAlerts/~4/cLlXitOErIY" height="1" width="1"/> Thu, 21 Jul 2011 04:00:00 GMT http://www.drugs.com/fda/multaq-dronedarone-safety-communication-increased-risk-death-serious-cardiovascular-events-13004.html http://feeds.drugs.com/~r/Drugscom-FdaMedwatchAlerts/~3/7Mf87gre7m8/oral-osteoporosis-bisphosphonates-safety-communication-potential-increased-risk-esophageal-cancer-13003.html Audience: Geriatrics, Family Practice, Internal Medicine Includes: Fosamax (alendronate), Actonel (risedronate), Boniva (ibandronate), Atelvia (risedronate delayed release), Didronel (etidronate), and Skelid (tiludronate) ISSUE: FDA notified... <p><a href="http://feedads.g.doubleclick.net/~a/tk4WPUKjH1DSR8J8hJ7B8CR0WiQ/0/da"><img src="http://feedads.g.doubleclick.net/~a/tk4WPUKjH1DSR8J8hJ7B8CR0WiQ/0/di" border="0" ismap="true"></img></a><br/> <a href="http://feedads.g.doubleclick.net/~a/tk4WPUKjH1DSR8J8hJ7B8CR0WiQ/1/da"><img src="http://feedads.g.doubleclick.net/~a/tk4WPUKjH1DSR8J8hJ7B8CR0WiQ/1/di" border="0" ismap="true"></img></a></p><img src="http://feeds.feedburner.com/~r/Drugscom-FdaMedwatchAlerts/~4/7Mf87gre7m8" height="1" width="1"/> Thu, 21 Jul 2011 04:00:00 GMT http://www.drugs.com/fda/oral-osteoporosis-bisphosphonates-safety-communication-potential-increased-risk-esophageal-cancer-13003.html http://feeds.drugs.com/~r/Drugscom-FdaMedwatchAlerts/~3/YFzEaZjPJuk/american-regent-injectable-products-recall-visible-particulates-products-13002.html Audience: Pharmacy Calcium Gluconate Injection, USP, 10%, 100 mL Pharmacy Bulk Package (Lot #1006) Concentrated Sodium Chloride Injection, USP 23.4%, 30 mL Single Dose Vials (Lot #0362) Methyldopate HCL Injection, USP 5ml Single Dose... <p><a href="http://feedads.g.doubleclick.net/~a/COCo2GdJpcTz7_RmKDT6AsKyiDA/0/da"><img src="http://feedads.g.doubleclick.net/~a/COCo2GdJpcTz7_RmKDT6AsKyiDA/0/di" border="0" ismap="true"></img></a><br/> <a href="http://feedads.g.doubleclick.net/~a/COCo2GdJpcTz7_RmKDT6AsKyiDA/1/da"><img src="http://feedads.g.doubleclick.net/~a/COCo2GdJpcTz7_RmKDT6AsKyiDA/1/di" border="0" ismap="true"></img></a></p><img src="http://feeds.feedburner.com/~r/Drugscom-FdaMedwatchAlerts/~4/YFzEaZjPJuk" height="1" width="1"/> Wed, 20 Jul 2011 04:00:00 GMT http://www.drugs.com/fda/american-regent-injectable-products-recall-visible-particulates-products-13002.html http://feeds.drugs.com/~r/Drugscom-FdaMedwatchAlerts/~3/nGlI1F6Q0qY/cardiogen-82-pet-scan-safety-communication-increased-radiation-exposure-13000.html Audience: Nuclear Medicine, Radiology, Patients ISSUE: FDA notified the public and the medical imaging community about the potential for inadvertent, increased radiation exposure in patients who underwent or will be undergoing cardiac positron... <p><a href="http://feedads.g.doubleclick.net/~a/gu0izImvUuktKKnujB2px0B_kYM/0/da"><img src="http://feedads.g.doubleclick.net/~a/gu0izImvUuktKKnujB2px0B_kYM/0/di" border="0" ismap="true"></img></a><br/> <a href="http://feedads.g.doubleclick.net/~a/gu0izImvUuktKKnujB2px0B_kYM/1/da"><img src="http://feedads.g.doubleclick.net/~a/gu0izImvUuktKKnujB2px0B_kYM/1/di" border="0" ismap="true"></img></a></p><img src="http://feeds.feedburner.com/~r/Drugscom-FdaMedwatchAlerts/~4/nGlI1F6Q0qY" height="1" width="1"/> Fri, 15 Jul 2011 04:00:00 GMT http://www.drugs.com/fda/cardiogen-82-pet-scan-safety-communication-increased-radiation-exposure-13000.html http://feeds.drugs.com/~r/Drugscom-FdaMedwatchAlerts/~3/r09mXHAjgLk/tamiflu-oseltamivir-phosphate-oral-suspension-label-change-new-concentration-6-mg-ml-12999.html Audience: Pediatrics, Pharmacy Patients may potentially receive either concentration (6 mg/mL or 12 mg/mL) from their pharmacy during the next influenza season (2011-2012). ISSUE: Labeling changes are being made to Tamiflu oral suspension to reduce... <p><a href="http://feedads.g.doubleclick.net/~a/PVpk2IExKtfRvkKk7JQ-pz1oGL8/0/da"><img src="http://feedads.g.doubleclick.net/~a/PVpk2IExKtfRvkKk7JQ-pz1oGL8/0/di" border="0" ismap="true"></img></a><br/> <a href="http://feedads.g.doubleclick.net/~a/PVpk2IExKtfRvkKk7JQ-pz1oGL8/1/da"><img src="http://feedads.g.doubleclick.net/~a/PVpk2IExKtfRvkKk7JQ-pz1oGL8/1/di" border="0" ismap="true"></img></a></p><img src="http://feeds.feedburner.com/~r/Drugscom-FdaMedwatchAlerts/~4/r09mXHAjgLk" height="1" width="1"/> Mon, 11 Jul 2011 04:00:00 GMT http://www.drugs.com/fda/tamiflu-oseltamivir-phosphate-oral-suspension-label-change-new-concentration-6-mg-ml-12999.html http://feeds.drugs.com/~r/Drugscom-FdaMedwatchAlerts/~3/NIX5BweTq0U/nulojix-belatacept-risk-evaluation-mitigation-strategy-rems-12996.html Audience: Transplantation, Nephrology Increased Risk of Post-transplant Lymphoproliferative Disorder (PTLD), predominantly involving the Central Nervous System (CNS), and Progressive Multifocal Leukoencephalopathy (PML) ISSUE: Bristol-Myers Squibb... <p><a href="http://feedads.g.doubleclick.net/~a/d8LuuhTzIsCJQSaxFo4e8zKiuvo/0/da"><img src="http://feedads.g.doubleclick.net/~a/d8LuuhTzIsCJQSaxFo4e8zKiuvo/0/di" border="0" ismap="true"></img></a><br/> <a href="http://feedads.g.doubleclick.net/~a/d8LuuhTzIsCJQSaxFo4e8zKiuvo/1/da"><img src="http://feedads.g.doubleclick.net/~a/d8LuuhTzIsCJQSaxFo4e8zKiuvo/1/di" border="0" ismap="true"></img></a></p><img src="http://feeds.feedburner.com/~r/Drugscom-FdaMedwatchAlerts/~4/NIX5BweTq0U" height="1" width="1"/> Thu, 07 Jul 2011 04:00:00 GMT http://www.drugs.com/fda/nulojix-belatacept-risk-evaluation-mitigation-strategy-rems-12996.html http://feeds.drugs.com/~r/Drugscom-FdaMedwatchAlerts/~3/_eKtKX_Fy70/valproate-products-safety-communication-risk-impaired-cognitive-development-children-exposed-utero-12994.html Audience: OBGYN, Neurology, Psychiatry Including valproate sodium (Depacon), divalproex sodium (Depakote, Depakote CP, and Depakote ER), valproic acid (Depakene and Stavzor), and their generics ISSUE: FDA notified healthcare professionals that... <p><a href="http://feedads.g.doubleclick.net/~a/UaWcYmOZJGV5fMlLFN1hHnUYDi8/0/da"><img src="http://feedads.g.doubleclick.net/~a/UaWcYmOZJGV5fMlLFN1hHnUYDi8/0/di" border="0" ismap="true"></img></a><br/> <a href="http://feedads.g.doubleclick.net/~a/UaWcYmOZJGV5fMlLFN1hHnUYDi8/1/da"><img src="http://feedads.g.doubleclick.net/~a/UaWcYmOZJGV5fMlLFN1hHnUYDi8/1/di" border="0" ismap="true"></img></a></p><img src="http://feeds.feedburner.com/~r/Drugscom-FdaMedwatchAlerts/~4/_eKtKX_Fy70" height="1" width="1"/> Thu, 30 Jun 2011 04:00:00 GMT http://www.drugs.com/fda/valproate-products-safety-communication-risk-impaired-cognitive-development-children-exposed-utero-12994.html http://feeds.drugs.com/~r/Drugscom-FdaMedwatchAlerts/~3/8ntaUMXMHPw/tylenol-extra-caplets-225-count-bottles-recall-uncharacteristic-odor-12995.html Audience: Pharmacy, Consumer ISSUE: McNeil Consumer Healthcare is recalling one product lot of Tylenol Extra Strength Caplets, 225 count bottles, distributed in the U.S. The recall stems from a small number of odor reports, including musty, moldy... <p><a href="http://feedads.g.doubleclick.net/~a/hELHBAqvXccFuwRe1pV2uyoqSiM/0/da"><img src="http://feedads.g.doubleclick.net/~a/hELHBAqvXccFuwRe1pV2uyoqSiM/0/di" border="0" ismap="true"></img></a><br/> <a href="http://feedads.g.doubleclick.net/~a/hELHBAqvXccFuwRe1pV2uyoqSiM/1/da"><img src="http://feedads.g.doubleclick.net/~a/hELHBAqvXccFuwRe1pV2uyoqSiM/1/di" border="0" ismap="true"></img></a></p><img src="http://feeds.feedburner.com/~r/Drugscom-FdaMedwatchAlerts/~4/8ntaUMXMHPw" height="1" width="1"/> Wed, 29 Jun 2011 04:00:00 GMT http://www.drugs.com/fda/tylenol-extra-caplets-225-count-bottles-recall-uncharacteristic-odor-12995.html http://feeds.drugs.com/~r/Drugscom-FdaMedwatchAlerts/~3/ZZn66OCUNng/butalbital-acetaminophen-caffeine-usp-50mg-325mg-40mg-hydrocodone-bitartrate-acetaminophen-usp-7-12993.html Audience: Pharmacy, Patient ISSUE: Qualitest and FDA is notifying pharmacists and patients of a recall to the retail level of specific lots of Butalbital, Acetaminophen, and Caffeine Tablets and Hydrocodone Bitartrate and Acetaminophen Tablets due... <p><a href="http://feedads.g.doubleclick.net/~a/_3b9Rapvh_TriU3cayU83NeQYyQ/0/da"><img src="http://feedads.g.doubleclick.net/~a/_3b9Rapvh_TriU3cayU83NeQYyQ/0/di" border="0" ismap="true"></img></a><br/> <a href="http://feedads.g.doubleclick.net/~a/_3b9Rapvh_TriU3cayU83NeQYyQ/1/da"><img src="http://feedads.g.doubleclick.net/~a/_3b9Rapvh_TriU3cayU83NeQYyQ/1/di" border="0" ismap="true"></img></a></p><img src="http://feeds.feedburner.com/~r/Drugscom-FdaMedwatchAlerts/~4/ZZn66OCUNng" height="1" width="1"/> Mon, 27 Jun 2011 04:00:00 GMT http://www.drugs.com/fda/butalbital-acetaminophen-caffeine-usp-50mg-325mg-40mg-hydrocodone-bitartrate-acetaminophen-usp-7-12993.html http://feeds.drugs.com/~r/Drugscom-FdaMedwatchAlerts/~3/S5ihb1Cofhg/endocet-oxycodone-acetaminophen-10mg-325mg-recall-some-bottles-contain-different-12992.html Audience: Pharmacy, Patients ISSUE: Endo Pharmaceuticals  and FDA notified pharmacists and patients of a nationwide consumer level recall of Endocet (oxycodone/acetaminophen, USP) Tablets, 10 mg/325 mg  because some bottles may contain different... <p><a href="http://feedads.g.doubleclick.net/~a/63HOQxdoqV72OLLTTAIwqkAZZKM/0/da"><img src="http://feedads.g.doubleclick.net/~a/63HOQxdoqV72OLLTTAIwqkAZZKM/0/di" border="0" ismap="true"></img></a><br/> <a href="http://feedads.g.doubleclick.net/~a/63HOQxdoqV72OLLTTAIwqkAZZKM/1/da"><img src="http://feedads.g.doubleclick.net/~a/63HOQxdoqV72OLLTTAIwqkAZZKM/1/di" border="0" ismap="true"></img></a></p><img src="http://feeds.feedburner.com/~r/Drugscom-FdaMedwatchAlerts/~4/S5ihb1Cofhg" height="1" width="1"/> Mon, 27 Jun 2011 04:00:00 GMT http://www.drugs.com/fda/endocet-oxycodone-acetaminophen-10mg-325mg-recall-some-bottles-contain-different-12992.html http://feeds.drugs.com/~r/Drugscom-FdaMedwatchAlerts/~3/Ns-4Kz137jg/nature-relief-instant-wart-mole-remover-recall-risk-severe-skin-burns-12991.html Audience: Consumer ISSUE: Nature Relief and FDA notified the public of a recall of Nature Relief Instant Wart and Mole Remover.  FDA has advised that the active ingredient, calcium oxide, can cause severe burns of the skin, particularly to areas of... <p><a href="http://feedads.g.doubleclick.net/~a/vPopiQm6aSkjPhvsiCqlNXDT1p4/0/da"><img src="http://feedads.g.doubleclick.net/~a/vPopiQm6aSkjPhvsiCqlNXDT1p4/0/di" border="0" ismap="true"></img></a><br/> <a href="http://feedads.g.doubleclick.net/~a/vPopiQm6aSkjPhvsiCqlNXDT1p4/1/da"><img src="http://feedads.g.doubleclick.net/~a/vPopiQm6aSkjPhvsiCqlNXDT1p4/1/di" border="0" ismap="true"></img></a></p><img src="http://feeds.feedburner.com/~r/Drugscom-FdaMedwatchAlerts/~4/Ns-4Kz137jg" height="1" width="1"/> Mon, 27 Jun 2011 04:00:00 GMT http://www.drugs.com/fda/nature-relief-instant-wart-mole-remover-recall-risk-severe-skin-burns-12991.html http://feeds.drugs.com/~r/Drugscom-FdaMedwatchAlerts/~3/ySEsnkc0JuQ/erythropoiesis-stimulating-agents-esas-chronic-kidney-safety-communication-modified-dosing-12990.html Audience: Nephrology, Oncology Epoetin alfa (marketed as Epogen and Procrit) and darbepoetin alfa (marketed as Aranesp) ISSUE: FDA notified healthcare professionals that new, modified recommendations for more conservative dosing of... <p><a href="http://feedads.g.doubleclick.net/~a/PHs4T0FSAQt_ckHkNXq7L4SNZoI/0/da"><img src="http://feedads.g.doubleclick.net/~a/PHs4T0FSAQt_ckHkNXq7L4SNZoI/0/di" border="0" ismap="true"></img></a><br/> <a href="http://feedads.g.doubleclick.net/~a/PHs4T0FSAQt_ckHkNXq7L4SNZoI/1/da"><img src="http://feedads.g.doubleclick.net/~a/PHs4T0FSAQt_ckHkNXq7L4SNZoI/1/di" border="0" ismap="true"></img></a></p><img src="http://feeds.feedburner.com/~r/Drugscom-FdaMedwatchAlerts/~4/ySEsnkc0JuQ" height="1" width="1"/> Fri, 24 Jun 2011 04:00:00 GMT http://www.drugs.com/fda/erythropoiesis-stimulating-agents-esas-chronic-kidney-safety-communication-modified-dosing-12990.html http://feeds.drugs.com/~r/Drugscom-FdaMedwatchAlerts/~3/ebhbvDnjVhg/risperdal-risperidone-risperidone-recall-uncharacteristic-odor-12989.html Audience: Pharmacy, Psychiatry, Neurology, Internal Medicine ISSUE: Ortho-McNeil-Janssen Pharmaceuticals notified healthcare professionals and the public of a recall of specific lots of Risperdal (risperidone) 3mg  tablets and risperidone 2mg... <p><a href="http://feedads.g.doubleclick.net/~a/aU7ojQ_mYTDzD5YzppxRb51MGjM/0/da"><img src="http://feedads.g.doubleclick.net/~a/aU7ojQ_mYTDzD5YzppxRb51MGjM/0/di" border="0" ismap="true"></img></a><br/> <a href="http://feedads.g.doubleclick.net/~a/aU7ojQ_mYTDzD5YzppxRb51MGjM/1/da"><img src="http://feedads.g.doubleclick.net/~a/aU7ojQ_mYTDzD5YzppxRb51MGjM/1/di" border="0" ismap="true"></img></a></p><img src="http://feeds.feedburner.com/~r/Drugscom-FdaMedwatchAlerts/~4/ebhbvDnjVhg" height="1" width="1"/> Mon, 20 Jun 2011 04:00:00 GMT http://www.drugs.com/fda/risperdal-risperidone-risperidone-recall-uncharacteristic-odor-12989.html http://feeds.drugs.com/~r/Drugscom-FdaMedwatchAlerts/~3/w-0LPPhMGIs/american-regent-injectable-products-recall-visible-particulates-products-12987.html Audience: Pharmacy Concentrated Sodium Chloride Injection, USP 23.4%, 30 mL Single Dose Vials (Lot #0362) Methyldopate HCL Injection, USP 5ml Single Dose Vial Caffeine & Sodium Benzoate Injection, USP, 250 mg/mL, 2 mL Single Dose Vial Ammonium... <p><a href="http://feedads.g.doubleclick.net/~a/JlXkSnCxsWVUZEnnJCmv-JbmGdY/0/da"><img src="http://feedads.g.doubleclick.net/~a/JlXkSnCxsWVUZEnnJCmv-JbmGdY/0/di" border="0" ismap="true"></img></a><br/> <a href="http://feedads.g.doubleclick.net/~a/JlXkSnCxsWVUZEnnJCmv-JbmGdY/1/da"><img src="http://feedads.g.doubleclick.net/~a/JlXkSnCxsWVUZEnnJCmv-JbmGdY/1/di" border="0" ismap="true"></img></a></p><img src="http://feeds.feedburner.com/~r/Drugscom-FdaMedwatchAlerts/~4/w-0LPPhMGIs" height="1" width="1"/> Thu, 16 Jun 2011 04:00:00 GMT http://www.drugs.com/fda/american-regent-injectable-products-recall-visible-particulates-products-12987.html http://feeds.drugs.com/~r/Drugscom-FdaMedwatchAlerts/~3/uhC5NdJDeFY/chantix-varenicline-label-change-risk-certain-cardiovascular-adverse-events-12986.html Audience: Family Medicine, Cardiology [Posted 06/16/2011] ISSUE: FDA notified healthcare professionals and patients that the Prescribing Information for this drug product will be strengthened to inform the public that use of varenicline may be... <p><a href="http://feedads.g.doubleclick.net/~a/UxqcvA1nhuSPP_Z-nuWTq2W0h60/0/da"><img src="http://feedads.g.doubleclick.net/~a/UxqcvA1nhuSPP_Z-nuWTq2W0h60/0/di" border="0" ismap="true"></img></a><br/> <a href="http://feedads.g.doubleclick.net/~a/UxqcvA1nhuSPP_Z-nuWTq2W0h60/1/da"><img src="http://feedads.g.doubleclick.net/~a/UxqcvA1nhuSPP_Z-nuWTq2W0h60/1/di" border="0" ismap="true"></img></a></p><img src="http://feeds.feedburner.com/~r/Drugscom-FdaMedwatchAlerts/~4/uhC5NdJDeFY" height="1" width="1"/> Thu, 16 Jun 2011 04:00:00 GMT http://www.drugs.com/fda/chantix-varenicline-label-change-risk-certain-cardiovascular-adverse-events-12986.html http://feeds.drugs.com/~r/Drugscom-FdaMedwatchAlerts/~3/0IEljH5JlHE/indomethacin-recall-one-lot-particulate-matter-12985.html [Posted 06/15/2011] AUDIENCE: Risk Manager, Pharmacy ISSUE: Bedford Laboratories, a division of Ben Venue Laboratories, Inc., initiated a nationwide voluntary recall of Indomethacin for Injection, USP, 1mg Single Dose Vial (NDC #55390-299-01, Lot... <p><a href="http://feedads.g.doubleclick.net/~a/6afRRXiJ_BTkAOXikVtM2UbkWzc/0/da"><img src="http://feedads.g.doubleclick.net/~a/6afRRXiJ_BTkAOXikVtM2UbkWzc/0/di" border="0" ismap="true"></img></a><br/> <a href="http://feedads.g.doubleclick.net/~a/6afRRXiJ_BTkAOXikVtM2UbkWzc/1/da"><img src="http://feedads.g.doubleclick.net/~a/6afRRXiJ_BTkAOXikVtM2UbkWzc/1/di" border="0" ismap="true"></img></a></p><img src="http://feeds.feedburner.com/~r/Drugscom-FdaMedwatchAlerts/~4/0IEljH5JlHE" height="1" width="1"/> Wed, 15 Jun 2011 04:00:00 GMT http://www.drugs.com/fda/indomethacin-recall-one-lot-particulate-matter-12985.html http://feeds.drugs.com/~r/Drugscom-FdaMedwatchAlerts/~3/5fn3uGuVff4/indomethacin-recall-particulate-matter-one-lot-12984.html Audience: Risk Manager, Pharmacy ISSUE: Bedford Laboratories, a division of Ben Venue Laboratories, Inc., initiated a nationwide voluntary recall of Indomethacin for Injection, USP, 1mg Single Dose Vial (NDC #55390-299-01, Lot 1948138, Exp. Date... <p><a href="http://feedads.g.doubleclick.net/~a/vR_Pi2kfnOF00w_AW8qLEp1O_Hk/0/da"><img src="http://feedads.g.doubleclick.net/~a/vR_Pi2kfnOF00w_AW8qLEp1O_Hk/0/di" border="0" ismap="true"></img></a><br/> <a href="http://feedads.g.doubleclick.net/~a/vR_Pi2kfnOF00w_AW8qLEp1O_Hk/1/da"><img src="http://feedads.g.doubleclick.net/~a/vR_Pi2kfnOF00w_AW8qLEp1O_Hk/1/di" border="0" ismap="true"></img></a></p><img src="http://feeds.feedburner.com/~r/Drugscom-FdaMedwatchAlerts/~4/5fn3uGuVff4" height="1" width="1"/> Wed, 15 Jun 2011 04:00:00 GMT http://www.drugs.com/fda/indomethacin-recall-particulate-matter-one-lot-12984.html http://feeds.drugs.com/~r/Drugscom-FdaMedwatchAlerts/~3/IPLWs424JNc/actos-pioglitazone-ongoing-safety-review-potential-increased-risk-bladder-cancer-12983.html Audience: Endocrinology, Family Practice, Urology [UPDATED 06/15/2011] Use of the diabetes medication Actos (pioglitazone) for more than one year may be associated with an increased risk of bladder cancer. Information about this risk will be added... <p><a href="http://feedads.g.doubleclick.net/~a/ZZLAWcsvbiXlo_qC7EXUjnX_oUo/0/da"><img src="http://feedads.g.doubleclick.net/~a/ZZLAWcsvbiXlo_qC7EXUjnX_oUo/0/di" border="0" ismap="true"></img></a><br/> <a href="http://feedads.g.doubleclick.net/~a/ZZLAWcsvbiXlo_qC7EXUjnX_oUo/1/da"><img src="http://feedads.g.doubleclick.net/~a/ZZLAWcsvbiXlo_qC7EXUjnX_oUo/1/di" border="0" ismap="true"></img></a></p><img src="http://feeds.feedburner.com/~r/Drugscom-FdaMedwatchAlerts/~4/IPLWs424JNc" height="1" width="1"/> Wed, 15 Jun 2011 04:00:00 GMT http://www.drugs.com/fda/actos-pioglitazone-ongoing-safety-review-potential-increased-risk-bladder-cancer-12983.html http://feeds.drugs.com/~r/Drugscom-FdaMedwatchAlerts/~3/cFGtKdMgh-8/victoza-liraglutide-rdna-origin-rems-risk-thyroid-c-cell-tumors-acute-pancreatitis-12979.html Audience: Endocrinology, Family Practice ISSUE: Novo Nordisk reminded healthcare professionals of important safety information about Victoza (liraglutide [rDNA origin]) injection required in a Risk Evaluation and Mitigation Strategy (REMS). The... <p><a href="http://feedads.g.doubleclick.net/~a/qz_FLUD7lPufI8wiygL28uV0wlQ/0/da"><img src="http://feedads.g.doubleclick.net/~a/qz_FLUD7lPufI8wiygL28uV0wlQ/0/di" border="0" ismap="true"></img></a><br/> <a href="http://feedads.g.doubleclick.net/~a/qz_FLUD7lPufI8wiygL28uV0wlQ/1/da"><img src="http://feedads.g.doubleclick.net/~a/qz_FLUD7lPufI8wiygL28uV0wlQ/1/di" border="0" ismap="true"></img></a></p><img src="http://feeds.feedburner.com/~r/Drugscom-FdaMedwatchAlerts/~4/cFGtKdMgh-8" height="1" width="1"/> Mon, 13 Jun 2011 04:00:00 GMT http://www.drugs.com/fda/victoza-liraglutide-rdna-origin-rems-risk-thyroid-c-cell-tumors-acute-pancreatitis-12979.html http://feeds.drugs.com/~r/Drugscom-FdaMedwatchAlerts/~3/dHIeFRzZbXM/risperidone-risperdal-ropinirole-requip-errors-confusion-12978.html Audience: Pharmacy, Psychiatry, Neurology, Internal Medicine ISSUE: FDA notified healthcare professionals and the public of medication error reports in which patients were given risperidone (Risperdal) instead of ropinirole (Requip) and vice versa.... <p><a href="http://feedads.g.doubleclick.net/~a/v1flv1LjaGWSL-Fb7ZpCl1FGFEQ/0/da"><img src="http://feedads.g.doubleclick.net/~a/v1flv1LjaGWSL-Fb7ZpCl1FGFEQ/0/di" border="0" ismap="true"></img></a><br/> <a href="http://feedads.g.doubleclick.net/~a/v1flv1LjaGWSL-Fb7ZpCl1FGFEQ/1/da"><img src="http://feedads.g.doubleclick.net/~a/v1flv1LjaGWSL-Fb7ZpCl1FGFEQ/1/di" border="0" ismap="true"></img></a></p><img src="http://feeds.feedburner.com/~r/Drugscom-FdaMedwatchAlerts/~4/dHIeFRzZbXM" height="1" width="1"/> Mon, 13 Jun 2011 04:00:00 GMT http://www.drugs.com/fda/risperidone-risperdal-ropinirole-requip-errors-confusion-12978.html http://feeds.drugs.com/~r/Drugscom-FdaMedwatchAlerts/~3/mgAoIxdPLP8/5-alpha-reductase-inhibitors-5-aris-label-change-increased-risk-prostate-cancer-12977.html Audience: Urology, Family Medicine, Internal Medicine Drugs in the 5-ARI class include finasteride and dutasteride. These drugs are marketed under the brand-names Proscar, Propecia, Avodart, and Jalyn ISSUE: FDA notified healthcare professionals... <p><a href="http://feedads.g.doubleclick.net/~a/ICe4-90wlkOUThRZgPmbFrdeDg8/0/da"><img src="http://feedads.g.doubleclick.net/~a/ICe4-90wlkOUThRZgPmbFrdeDg8/0/di" border="0" ismap="true"></img></a><br/> <a href="http://feedads.g.doubleclick.net/~a/ICe4-90wlkOUThRZgPmbFrdeDg8/1/da"><img src="http://feedads.g.doubleclick.net/~a/ICe4-90wlkOUThRZgPmbFrdeDg8/1/di" border="0" ismap="true"></img></a></p><img src="http://feeds.feedburner.com/~r/Drugscom-FdaMedwatchAlerts/~4/mgAoIxdPLP8" height="1" width="1"/> Thu, 09 Jun 2011 04:00:00 GMT http://www.drugs.com/fda/5-alpha-reductase-inhibitors-5-aris-label-change-increased-risk-prostate-cancer-12977.html http://feeds.drugs.com/~r/Drugscom-FdaMedwatchAlerts/~3/gnfME_F8MQk/triad-alcohol-prep-pads-alcohol-swabs-alcohol-swabsticks-recall-due-potential-microbial-12976.html Audience: Pharmacy, Consumer, Risk Manager [UPDATED 06/08/2011] Churchill Medical Systems, A Vygon Company, initiated a nationwide recall of certain lots of Skin-Prep Wipes used in Convenience Kits. The Skin-Prep Wipes were manufactured in the same... <p><a href="http://feedads.g.doubleclick.net/~a/nHO-jhUkFwa_sB8fxCGDzzVdEF4/0/da"><img src="http://feedads.g.doubleclick.net/~a/nHO-jhUkFwa_sB8fxCGDzzVdEF4/0/di" border="0" ismap="true"></img></a><br/> <a href="http://feedads.g.doubleclick.net/~a/nHO-jhUkFwa_sB8fxCGDzzVdEF4/1/da"><img src="http://feedads.g.doubleclick.net/~a/nHO-jhUkFwa_sB8fxCGDzzVdEF4/1/di" border="0" ismap="true"></img></a></p><img src="http://feeds.feedburner.com/~r/Drugscom-FdaMedwatchAlerts/~4/gnfME_F8MQk" height="1" width="1"/> Wed, 08 Jun 2011 04:00:00 GMT http://www.drugs.com/fda/triad-alcohol-prep-pads-alcohol-swabs-alcohol-swabsticks-recall-due-potential-microbial-12976.html http://feeds.drugs.com/~r/Drugscom-FdaMedwatchAlerts/~3/Bo7uX_oWOKg/zocor-simvastatin-label-change-new-restrictions-contraindications-limitations-12975.html Audience: Family Practice, Cardiology, Pharmacy Simvastatin sold under the brand-name Zocor, as a single-ingredient generic product, and sold in combination with ezetimibe as Vytorin and in combination with niacin as Simcor [Posted... <p><a href="http://feedads.g.doubleclick.net/~a/erjW-DFS3JE1hXX0QwqKFPMeOws/0/da"><img src="http://feedads.g.doubleclick.net/~a/erjW-DFS3JE1hXX0QwqKFPMeOws/0/di" border="0" ismap="true"></img></a><br/> <a href="http://feedads.g.doubleclick.net/~a/erjW-DFS3JE1hXX0QwqKFPMeOws/1/da"><img src="http://feedads.g.doubleclick.net/~a/erjW-DFS3JE1hXX0QwqKFPMeOws/1/di" border="0" ismap="true"></img></a></p><img src="http://feeds.feedburner.com/~r/Drugscom-FdaMedwatchAlerts/~4/Bo7uX_oWOKg" height="1" width="1"/> Wed, 08 Jun 2011 04:00:00 GMT http://www.drugs.com/fda/zocor-simvastatin-label-change-new-restrictions-contraindications-limitations-12975.html http://feeds.drugs.com/~r/Drugscom-FdaMedwatchAlerts/~3/A4agXZa0Rq8/american-regent-injectable-products-recall-visible-particulates-products-12974.html Audience: Pharmacy Methyldopate HCL Injection, USP 5ml Single Dose Vial Caffeine & Sodium Benzoate Injection, USP, 250 mg/mL, 2 mL Single Dose Vial Ammonium Molybdate Injection, USP (Molybdenum 250mcg/10 mL) 10 mL Single Dose Vial Dexamethasone... <p><a href="http://feedads.g.doubleclick.net/~a/3bbH94zeVs0EVAhN5Y3TmcXXzIk/0/da"><img src="http://feedads.g.doubleclick.net/~a/3bbH94zeVs0EVAhN5Y3TmcXXzIk/0/di" border="0" ismap="true"></img></a><br/> <a href="http://feedads.g.doubleclick.net/~a/3bbH94zeVs0EVAhN5Y3TmcXXzIk/1/da"><img src="http://feedads.g.doubleclick.net/~a/3bbH94zeVs0EVAhN5Y3TmcXXzIk/1/di" border="0" ismap="true"></img></a></p><img src="http://feeds.feedburner.com/~r/Drugscom-FdaMedwatchAlerts/~4/A4agXZa0Rq8" height="1" width="1"/> Tue, 07 Jun 2011 04:00:00 GMT http://www.drugs.com/fda/american-regent-injectable-products-recall-visible-particulates-products-12974.html http://feeds.drugs.com/~r/Drugscom-FdaMedwatchAlerts/~3/Rzee7KZSmcE/via-xtreme-ultimate-sexual-enhancer-dietary-supplement-men-recall-undeclared-ingredient-12972.html Audience: Consumer ISSUE: FDA lab analyses found Via Xtreme Ultimate Sexual Enhancer Dietary Supplement for Men to contain sulfoaildenafil methanesulfonate, sulfosildenafil and dimethylsildenafil analogs of sildenafil. The active drug ingredients... <p><a href="http://feedads.g.doubleclick.net/~a/VN3cfksfHoSRny425PQU_x0DDmc/0/da"><img src="http://feedads.g.doubleclick.net/~a/VN3cfksfHoSRny425PQU_x0DDmc/0/di" border="0" ismap="true"></img></a><br/> <a href="http://feedads.g.doubleclick.net/~a/VN3cfksfHoSRny425PQU_x0DDmc/1/da"><img src="http://feedads.g.doubleclick.net/~a/VN3cfksfHoSRny425PQU_x0DDmc/1/di" border="0" ismap="true"></img></a></p><img src="http://feeds.feedburner.com/~r/Drugscom-FdaMedwatchAlerts/~4/Rzee7KZSmcE" height="1" width="1"/> Tue, 07 Jun 2011 04:00:00 GMT http://www.drugs.com/fda/via-xtreme-ultimate-sexual-enhancer-dietary-supplement-men-recall-undeclared-ingredient-12972.html http://feeds.drugs.com/~r/Drugscom-FdaMedwatchAlerts/~3/hJLNJTnusSs/simplythick-public-health-notification-risk-threatening-bowel-condition-12971.html Audience: Consumers, Pediatrics, Emergency medicine [Updated 06/05/2011] Simply Thick, LLC is announcing a voluntary recall of its SimplyThick thickening gel products manufactured at a food processing plant owned and operated by Thermo Pac, LLC.... <p><a href="http://feedads.g.doubleclick.net/~a/_NlDV8QzdA5THNCnATFhz7wMR7o/0/da"><img src="http://feedads.g.doubleclick.net/~a/_NlDV8QzdA5THNCnATFhz7wMR7o/0/di" border="0" ismap="true"></img></a><br/> <a href="http://feedads.g.doubleclick.net/~a/_NlDV8QzdA5THNCnATFhz7wMR7o/1/da"><img src="http://feedads.g.doubleclick.net/~a/_NlDV8QzdA5THNCnATFhz7wMR7o/1/di" border="0" ismap="true"></img></a></p><img src="http://feeds.feedburner.com/~r/Drugscom-FdaMedwatchAlerts/~4/hJLNJTnusSs" height="1" width="1"/> Sun, 05 Jun 2011 04:00:00 GMT http://www.drugs.com/fda/simplythick-public-health-notification-risk-threatening-bowel-condition-12971.html http://feeds.drugs.com/~r/Drugscom-FdaMedwatchAlerts/~3/D7ICjFLg-yY/aidapak-services-repackaged-pharmaceuticals-recall-potential-cross-contamination-beta-lactam-12970.html Audience: Pharmacy, Risk Manager ISSUE: FDA and Aidapak Services notified healthcare professionals and hospital pharmacies of a nationwide recall of multiple repackaged drug products after learning of the potential cross contamination of... <p><a href="http://feedads.g.doubleclick.net/~a/AyppeKpPu_UQChbOThLMzbzehHs/0/da"><img src="http://feedads.g.doubleclick.net/~a/AyppeKpPu_UQChbOThLMzbzehHs/0/di" border="0" ismap="true"></img></a><br/> <a href="http://feedads.g.doubleclick.net/~a/AyppeKpPu_UQChbOThLMzbzehHs/1/da"><img src="http://feedads.g.doubleclick.net/~a/AyppeKpPu_UQChbOThLMzbzehHs/1/di" border="0" ismap="true"></img></a></p><img src="http://feeds.feedburner.com/~r/Drugscom-FdaMedwatchAlerts/~4/D7ICjFLg-yY" height="1" width="1"/> Fri, 03 Jun 2011 04:00:00 GMT http://www.drugs.com/fda/aidapak-services-repackaged-pharmaceuticals-recall-potential-cross-contamination-beta-lactam-12970.html http://feeds.drugs.com/~r/Drugscom-FdaMedwatchAlerts/~3/G3Shn1Nk4Oo/angiotensin-receptor-blockers-arbs-safety-communication-safety-review-completed-12969.html Audience: Cardiology, Oncology, Family Practice [UPDATED 06/02/2011] FDA’s meta-analysis of 31 randomized controlled trials comparing ARBs to other treatment found no evidence of an increased risk of incident (new) cancer, cancer-related death,... <p><a href="http://feedads.g.doubleclick.net/~a/IVrPJFkXZ3u71lndi5wNOq5wJyk/0/da"><img src="http://feedads.g.doubleclick.net/~a/IVrPJFkXZ3u71lndi5wNOq5wJyk/0/di" border="0" ismap="true"></img></a><br/> <a href="http://feedads.g.doubleclick.net/~a/IVrPJFkXZ3u71lndi5wNOq5wJyk/1/da"><img src="http://feedads.g.doubleclick.net/~a/IVrPJFkXZ3u71lndi5wNOq5wJyk/1/di" border="0" ismap="true"></img></a></p><img src="http://feeds.feedburner.com/~r/Drugscom-FdaMedwatchAlerts/~4/G3Shn1Nk4Oo" height="1" width="1"/> Thu, 02 Jun 2011 04:00:00 GMT http://www.drugs.com/fda/angiotensin-receptor-blockers-arbs-safety-communication-safety-review-completed-12969.html